It’s easy to assume that an investment trust with the word “income” in its title is very much in the “value” camp, investing in companies with high dividends but that are mature, declining or mis-managed businesses.
Charles Luke, the manager of the £1bn Murray Income Trust (LSE: MUT) has different ideas, emphasising the importance of “quality” companies. This means those with high returns on invested capital based on the durability of the business model, the attractiveness of the industry, the strength of its financials, the capability of its management and a good environmental, social and governance (ESG) profile.
“The academic evidence is very clear,” he says. “Good quality companies out-perform because the market systematically underestimates the sustainability of their returns. Quality is the key to long-term success.” The price of this is a portfolio “that is a little bit expensive in terms of valuation, a price/earnings ratio of perhaps two to three points higher than the market”.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The trust, which invests primarily in UK equities, yields 3.8% and has increased its dividend annually for the last 48 years. The compound growth rate over that period is 9.4%.The yield is helped by the 6% discount to net asset value (NAV) at which the shares trade and its low costs (a total expenses ratio below 0.5%), but a yield well above the All Share index’s 3.1% is still impressive.
A well-diversified portfolio
The yield is not boosted by having a third of the portfolio in mid-cap stocks, generally lower yielding than the FTSE 100, and 12% of the portfolio invested overseas. This is balanced by low-cost borrowings, amounting to 9% of NAV, the capitalisation of 70% of interest and management costs, and an option writing strategy that accounts for 5%-7% of total income. Luke calls this “a tried and tested process that we have been doing for over ten years”.
The portfolio has 61 holdings, none larger than 5%, and is well-diversified by sector. The largest holdings are AstraZeneca, Diageo, RELX and SSE but the overlap with the FTSE All-Share index is just 30%. The overseas investments, which can be up to 20% of the total, enable Luke “to invest in better quality versions of UK companies” such as Total rather than Shell “and in companies in industries that aren’t available to UK investors”, such as VAT Group, the market leader in vacuum valve technology.
Mid-cap holdings give access “high-quality domestic companies” such as Genuit (plastic piping) and Howden Joinery (fitted kitchens), and also firms with “under-appreciated quality” such as Convatec (medical products) and Inchcape (international car dealerships)”. Luke is also prepared to invest in companies with low yields but growth potential, such as Dechra Pharmaceuticals and the technology group Aveva.
A strong all-round performer
The result is both an attractive and growing yield and one of the best performance records in the UK. Investment returns to the end of 2021 were 18% over one year, 45% over three and 47% over five – the latter two 17 percentage points ahead of the All Share index. Moreover, Luke can point to a strong record of capital preservation. In the last ten years, the trust has marginally under-performed in up months for the market but significantly out-performed in down months.
“UK equity valuations remain compelling compared with other markets, the UK offers compelling global growth opportunities and international investors are underweight, despite the proliferation of bid activity,” reckons Luke. London cannot swim against what is currently an adverse tide in stockmarkets but the yield and record of resilience in tough times should reassure investors and pay them to wait, confident that the trust is well positioned for better times.
Merryn Somerset Webb is a non-executive director of Murray Income Trust.
-
Charitable giving and inheritance tax: 7 tips to avoid complicationsGiving some of your estate away to charity can save your family thousands in inheritance tax. But common pitfalls could mean your chosen cause loses out and your loved ones are left with a complex nightmare to unravel. We look at how to do donations right.
-
The UK cities where it’s cheaper to buy a house than rentFor people in some areas of the country, home ownership is a distant dream. But for others it can be surprisingly affordable.
-
Pierre-Édouard Stérin wants to make France great againConservative billionaire Pierre-Édouard Stérin is seeking to lead a political and spiritual renaissance across the Channel. The planning looks meticulous
-
Global investors have overlooked the top innovators in emerging marketsOpinion Carlos Hardenberg, portfolio manager, Mobius Investment Trust, highlights three emerging market stocks where he’d put his money
-
Pinewood Technologies: a drive for growthPinewood Technologies’ platform is one of the best in the business. Investors should buy in
-
'EV maker Faraday Future will crash'Faraday Future Intelligent Electric is failing dismally to live up to its name, says Matthew Partridge
-
Investors should cheer the coming nuclear summerThe US and UK have agreed a groundbreaking deal on nuclear power, and the sector is seeing a surge in interest from around the world. Here's how you can profit
-
8 of the best houses for sale with folliesThe best houses for sale with follies in the grounds – from a five-storey Victorian Gothic tower in Tonbridge, Kent, to a former mill in Oxfordshire with gardens that include a folly on an island in a lake
-
A tale of two Reits – why performance matters for valuationAEW UK and Regional are two Reits that are valued very differently, despite a shared focus on properties outside London
-
Healthcare stocks look cheap, but tread carefullyShares in healthcare companies could get a shot in the arm if uncertainty over policy in the US wanes, but are they worth the risk?
